Logo image of INBS

INTELLIGENT BIO SOLUTIONS IN (INBS) Stock Fundamental Analysis

NASDAQ:INBS - Nasdaq - US36151G6008 - Common Stock - Currency: USD

1.3  +0.07 (+5.69%)

Premarket: 1.3799 +0.08 (+6.15%)

Fundamental Rating

3

Overall INBS gets a fundamental rating of 3 out of 10. We evaluated INBS against 191 industry peers in the Health Care Equipment & Supplies industry. INBS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. INBS is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year INBS has reported negative net income.
In the past year INBS has reported a negative cash flow from operations.
In the past 5 years INBS always reported negative net income.
In the past 5 years INBS always reported negative operating cash flow.
INBS Yearly Net Income VS EBIT VS OCF VS FCFINBS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

INBS has a worse Return On Assets (-123.18%) than 84.82% of its industry peers.
INBS has a worse Return On Equity (-245.01%) than 77.49% of its industry peers.
Industry RankSector Rank
ROA -123.18%
ROE -245.01%
ROIC N/A
ROA(3y)-81.21%
ROA(5y)-80.72%
ROE(3y)-175.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INBS Yearly ROA, ROE, ROICINBS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K 2.5K

1.3 Margins

INBS has a Gross Margin (51.59%) which is comparable to the rest of the industry.
INBS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 51.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INBS Yearly Profit, Operating, Gross MarginsINBS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -1M -2M -3M

More info and screens

4

2. Health

2.1 Basic Checks

INBS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for INBS has been increased compared to 1 year ago.
INBS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, INBS has an improved debt to assets ratio.
INBS Yearly Shares OutstandingINBS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
INBS Yearly Total Debt VS Total AssetsINBS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -11.73, we must say that INBS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -11.73, INBS is doing worse than 79.06% of the companies in the same industry.
There is no outstanding debt for INBS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.73
ROIC/WACCN/A
WACC9.07%
INBS Yearly LT Debt VS Equity VS FCFINBS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M 15M

2.3 Liquidity

INBS has a Current Ratio of 0.92. This is a bad value and indicates that INBS is not financially healthy enough and could expect problems in meeting its short term obligations.
INBS's Current ratio of 0.92 is on the low side compared to the rest of the industry. INBS is outperformed by 89.53% of its industry peers.
INBS has a Quick Ratio of 0.92. This is a bad value and indicates that INBS is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.76, INBS is not doing good in the industry: 84.82% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.92
Quick Ratio 0.76
INBS Yearly Current Assets VS Current LiabilitesINBS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 97.30% over the past year.
The Revenue has grown by 23.21% in the past year. This is a very strong growth!
Measured over the past years, INBS shows a very strong growth in Revenue. The Revenue has been growing by 589.28% on average per year.
EPS 1Y (TTM)97.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.01%
Revenue 1Y (TTM)23.21%
Revenue growth 3Y16.26%
Revenue growth 5Y589.28%
Sales Q2Q%-20.48%

3.2 Future

Based on estimates for the next years, INBS will show a very strong growth in Earnings Per Share. The EPS will grow by 44.75% on average per year.
INBS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 150.78% yearly.
EPS Next Y65.94%
EPS Next 2Y44.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year177.96%
Revenue Next 2Y150.78%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
INBS Yearly Revenue VS EstimatesINBS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M 25M
INBS Yearly EPS VS EstimatesINBS Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 0 -50 -100 -150

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

INBS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 3.64, which indicates a rather cheap valuation of INBS.
Based on the Price/Forward Earnings ratio, INBS is valued cheaper than 99.48% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.65. INBS is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 3.64
INBS Price Earnings VS Forward Price EarningsINBS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INBS Per share dataINBS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

INBS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
INBS's earnings are expected to grow with 44.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.75%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INBS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTELLIGENT BIO SOLUTIONS IN

NASDAQ:INBS (4/24/2025, 8:17:57 PM)

Premarket: 1.3799 +0.08 (+6.15%)

1.3

+0.07 (+5.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners1.63%
Inst Owner Change0%
Ins Owners1.03%
Ins Owner Change0%
Market Cap8.81M
Analysts85.71
Price Target12.24 (841.54%)
Short Float %6.76%
Short Ratio2.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-62.34%
Min Revenue beat(2)-73.53%
Max Revenue beat(2)-51.15%
Revenue beat(4)0
Avg Revenue beat(4)-51.73%
Min Revenue beat(4)-73.53%
Max Revenue beat(4)-32.13%
Revenue beat(8)0
Avg Revenue beat(8)-38.37%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.64
P/S 2.91
P/FCF N/A
P/OCF N/A
P/B 2.02
P/tB 19.02
EV/EBITDA N/A
EPS(TTM)-3.55
EYN/A
EPS(NY)0.36
Fwd EY27.46%
FCF(TTM)-1.49
FCFYN/A
OCF(TTM)-1.49
OCFYN/A
SpS0.45
BVpS0.64
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -123.18%
ROE -245.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 51.59%
FCFM N/A
ROA(3y)-81.21%
ROA(5y)-80.72%
ROE(3y)-175.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.92
Quick Ratio 0.76
Altman-Z -11.73
F-Score6
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.01%
EPS Next Y65.94%
EPS Next 2Y44.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)23.21%
Revenue growth 3Y16.26%
Revenue growth 5Y589.28%
Sales Q2Q%-20.48%
Revenue Next Year177.96%
Revenue Next 2Y150.78%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-60.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-60.61%
OCF growth 3YN/A
OCF growth 5YN/A